acebutolol has been researched along with Bowel Diseases, Inflammatory in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 28 (77.78) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Casà, A; Crispino, F; Grova, M; Macaluso, FS; Maida, M; Mannino, M; Orlando, A; Renna, S; Rizzuto, G | 1 |
| Fuyuno, Y; Harada, A; Matsuno, Y; Morisaki, S; Saiki, T; Suekane, H; Suzuki, T; Taniguchi, Y; Torisu, T; Umeno, J | 1 |
| Aliu, A; Bertrams Maartens, IA; Bevers, N; Escher, H; Oudshoorn, A; Pierik, MJ; Raijmakers, M; Rezazadeh Ardabili, A; Rosias, P; Stapelbroek, J; Teklenburg, S; van de Feen, C; Van de Vijver, E; van Rheenen, PF; Vande Velde, S; Vreugdenhil, A; Winkens, B | 1 |
| Musgrove, J; Wolf, M | 1 |
| Detlie, TE; Jahnsen, J | 1 |
| Farland, MZ; Khoury, A; Pagan, KA | 1 |
| Borrelli, O; Chadokufa, S; Cococcioni, L; El-Khouly, S; Kiparissi, F; McCartney, S; Pensabene, L; Saliakellis, E | 1 |
| Bokemeyer, B; Domènech, E; Howaldt, S; Martinez, N; Schmidt, C | 1 |
| Boccia, S; Di Pietro, ML; Fabrizio, L; Favaretti, C; Gasbarrini, A; Kheiraoui, F; Poscia, A; Proli, EM; Scaldaferri, F; Stojanovic, J; Volpe, M | 1 |
| Boccia, S; Canarecci, S; Ciancarella, G; Collamati, A; de Waure, C; Gasbarrini, A; Kheiraoui, F; Milovanovic, S; Poscia, A; Scaldaferri, F; Schiavoni, E | 1 |
| Muduma, G; Pollock, RF | 3 |
| Arkkila, P; Färkkilä, M; Haapamäki, J; Kangaspunta, M | 1 |
| Scott, LJ | 1 |
| Aksan, A; Dignass, A; Stein, J | 1 |
| Detlie, TE; Finnes, E; Jahnsen, J; Jahnsen, ME; Lindstrøm, JC; Moum, B; Zoller, H | 1 |
| Evstatiev, R; Gasche, C; Howaldt, S; Kamali, H; Kulnigg-Dabsch, S; Mickisch, O; Schmid, W; Stein, J; Volf, I; Waldhör, T | 1 |
| Li, Y; Wang, H; Zhu, W; Zuo, L | 1 |
| Gasche, C; Kulnigg-Dabsch, S | 1 |
| Gisbert, JP; Gomollón, F | 2 |
| Allocca, M; Danese, S; Fiorino, G | 1 |
| Chainey, S; Cushway, T; Laass, MW; Straub, S; Virgin, G | 1 |
| Borrás-Blasco, J; Boscá, M; Cortés, E; Cortes, X; Molés, JR | 1 |
| Bajador, E; Bocos, JM; Castaño, C; Chaparro, M; García-Erce, JA; García-López, S; Gisbert, JP; Gomollón, F | 1 |
| Gearry, RB | 1 |
| Ghaly, S | 1 |
| García-Erce, JA; Gómez-Ramírez, S; Muñoz, M | 1 |
| Bailie, GR | 1 |
| Bager, P; Dahlerup, JF | 1 |
| Bokemeyer, B; Chopey, IV; Evstatiev, R; Gasche, C; Gutzwiller, FS; Iqbal, T; Khalif, IL; Marteau, P; Riopel, L; Stein, J | 1 |
| Beigel, F; Brand, S; Breiteneicher, S; Göke, B; Laubender, RP; Löhr, B; Ochsenkühn, T; Schnitzler, F; Seiderer, J; Tillack, C; Weidinger, M | 1 |
| Bhandari, S; Muñoz, M; Reinisch, W; Staun, M | 1 |
| Alexeeva, O; Bokemeyer, B; Chopey, I; Evstatiev, R; Felder, M; Gasche, C; Gudehus, M; Iqbal, T; Khalif, I; Marteau, P; Stein, J | 1 |
7 review(s) available for acebutolol and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Clinical Trials as Topic; Female; Ferric Compounds; Hematinics; Humans; Inflammatory Bowel Diseases; Male; Maltose; Pyrones; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Ferric Carboxymaltose: A Review in Iron Deficiency.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Chronic Disease; Female; Ferric Compounds; Heart Failure; Humans; Inflammatory Bowel Diseases; Kidney Diseases; Maltose; Neoplasms; Postpartum Period; Pregnancy; Treatment Outcome; Uterine Hemorrhage | 2018 |
Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide.
Topics: Anemia, Iron-Deficiency; Animals; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Iron; Maltose | 2013 |
Iron deficiency: the hidden miscreant in inflammatory bowel disease.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Clinical Trials as Topic; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Maltose; Quality of Life | 2014 |
Intravenous iron in inflammatory bowel disease.
Topics: Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gluconates; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Injections, Intraventricular; Iron; Iron-Dextran Complex; Maltose; Treatment Outcome | 2009 |
State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease.
Topics: Algorithms; Anemia, Iron-Deficiency; Clinical Trials as Topic; Diagnosis, Differential; Disaccharides; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron Deficiencies; Maltose; Prevalence; Thrombocytosis; Thromboembolism | 2013 |
6 trial(s) available for acebutolol and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial.
Topics: Administration, Oral; Anemia; Anemia, Iron-Deficiency; Child; Ferric Compounds; Hemoglobins; Humans; Inflammatory Bowel Diseases; Iron; Maltose; Treatment Outcome | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Hemoglobins; Humans; Inflammatory Bowel Diseases; Male; Maltose; Pyrones; Treatment Outcome | 2022 |
Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Erythropoietin; Female; Ferric Compounds; Hepcidins; Humans; Inflammatory Bowel Diseases; Intercellular Signaling Peptides and Proteins; Male; Maltose; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Count; Prognosis; Prospective Studies; Thrombocytosis; Young Adult | 2013 |
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Comorbidity; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Middle Aged; Outcome Assessment, Health Care; Treatment Outcome; Young Adult | 2011 |
Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Dietary Supplements; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Middle Aged; Placebos; Secondary Prevention; Single-Blind Method; Treatment Outcome; Young Adult | 2013 |
24 other study(ies) available for acebutolol and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.
Topics: Anemia, Iron-Deficiency; Chronic Disease; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Retrospective Studies; Treatment Outcome | 2022 |
[A case of chronic enteropathy associated with SLCO2A1 gene diagnosed by capsule endoscopy and successfully treated by ferric carboxymaltose].
Topics: Anemia; Anemia, Iron-Deficiency; Capsule Endoscopy; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Iron; Maltose; Middle Aged; Organic Anion Transporters; Ulcer | 2022 |
Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.
Topics: Disaccharides; Ferric Compounds; Humans; Hypophosphatemia; Incidence; Inflammatory Bowel Diseases; Iron; Maltose | 2019 |
Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia. Authors' reply.
Topics: Disaccharides; Ferric Compounds; Humans; Hypophosphatemia; Incidence; Inflammatory Bowel Diseases; Iron; Maltose | 2019 |
Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
Topics: Administration, Intravenous; Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Hypophosphatemia; Inflammatory Bowel Diseases; Iron; Male; Maltose; Phosphates; Prevalence; Risk Factors; Severity of Illness Index; Treatment Outcome | 2021 |
Sustainability of Endovenous Iron Deficiency Anaemia Treatment: Hospital-Based Health Technology Assessment in IBD Patients.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Ferric Compounds; Hemoglobins; Hospitals; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron; Italy; Maltose; Technology Assessment, Biomedical; Treatment Outcome | 2017 |
Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease.
Topics: Absenteeism; Administration, Intravenous; Administration, Oral; Adult; Anemia; Caregivers; Cost of Illness; Cross-Sectional Studies; Employment; Female; Ferric Compounds; Health Care Surveys; Hemoglobins; Humans; Inflammatory Bowel Diseases; Iron; Male; Maltose; Middle Aged; Patient Preference; Severity of Illness Index | 2017 |
Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
Topics: Anemia, Iron-Deficiency; Budgets; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron-Dextran Complex; Maltose; Retrospective Studies; United Kingdom | 2017 |
Inflammatory bowel disease and anemia: intravenous iron treatment.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Exanthema; Female; Ferric Compounds; Ferritins; Finland; Humans; Inflammatory Bowel Diseases; Iron; Linear Models; Male; Maltose; Middle Aged; Nausea; Receptors, Transferrin; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Denmark; Disaccharides; Female; Ferric Compounds; Hemoglobins; Humans; Inflammatory Bowel Diseases; Maltose; Middle Aged; Retrospective Studies | 2018 |
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Denmark; Disaccharides; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Maltose | 2019 |
Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Denmark; Disaccharides; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Maltose | 2019 |
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Disaccharides; Female; Ferric Compounds; Humans; Hypophosphatemia; Incidence; Inflammatory Bowel Diseases; Male; Maltose; Middle Aged; Norway; Prospective Studies; Quality of Life; Risk Factors | 2019 |
Iron deficiency generates secondary thrombocytosis and platelet activation in inflammatory bowel disease : the randomized, controlled ThromboVIT trial.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Platelet Activation; Thrombocytosis | 2013 |
Reply to Zuo et al.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Platelet Activation; Thrombocytosis | 2013 |
Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Gastrointestinal Diseases; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Retrospective Studies; Treatment Outcome | 2014 |
Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Topics: Adult; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Administration Schedule; Ferric Compounds; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Infusions, Intravenous; Male; Maltose; Middle Aged; Patient Compliance; Pilot Projects; Prospective Studies; Treatment Outcome | 2015 |
High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Middle Aged; Prospective Studies; Quality of Life; Young Adult | 2016 |
Introduction.
Topics: Antibodies, Monoclonal, Humanized; Ferric Compounds; Health Facilities; Humans; Inflammatory Bowel Diseases; Infliximab; Infusions, Intravenous; Maltose; Patient Compliance; Patient Education as Topic | 2016 |
Iron and vitamin D deficiency in inflammatory bowel disease.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Cholecalciferol; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Injections, Intramuscular; Maltose; Vitamin D Deficiency | 2016 |
Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Topics: Anemia; Anemia, Iron-Deficiency; Breast Feeding; Female; Ferric Compounds; Ferritins; Heart Failure; Humans; Infant; Inflammatory Bowel Diseases; Maltose; Pilot Projects; Puerperal Disorders; Randomized Controlled Trials as Topic; Renal Insufficiency; Safety; Transferrin | 2010 |
The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Costs; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Health Care Costs; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Middle Aged; Young Adult | 2010 |
IBD: Intravenous iron in IBD--what's the best preparation?
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Inflammatory Bowel Diseases; Injections, Intravenous; Maltose; Quality of Life; Treatment Outcome | 2011 |
Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Cohort Studies; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Treatment Outcome; Young Adult | 2012 |